CC
MCID: CHL065
MIFTS: 58

Cholangiocarcinoma (CC)

Categories: Liver diseases, Rare diseases

Aliases & Classifications for Cholangiocarcinoma

MalaCards integrated aliases for Cholangiocarcinoma:

Name: Cholangiocarcinoma 57 73 43 58 36 29 54 6 37 17 70
Cholangiocarcinoma, Susceptibility to 57 29
Intrahepatic Cholangiocarcinoma 43 70
Extrahepatic Cholangiocarcinoma 43 70
Adult Primary Cholangiocellular Carcinoma 70
Cholangiocarcinoma of Biliary Tract 43
Perihilar Cholangiocarcinoma 43
Cholangiocellular Carcinoma 43
Distal Cholangiocarcinoma 43
Chlc, Susceptibility to 57
Bile Duct Carcinoma 70
Bile Duct Cancer 58
Chlc 57
Cca 58
Cc 43

Characteristics:

Orphanet epidemiological data:

58
cholangiocarcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

OMIM® 57 615619
KEGG 36 H00046
MESH via Orphanet 45 D001650 D018281
ICD10 via Orphanet 33 C22.1 C24.0 C24.8 more
UMLS via Orphanet 71 C0206698 C0740277
Orphanet 58 ORPHA70567
MedGen 41 C3810156
UMLS 70 C0206698 C0280725 C0345905 more

Summaries for Cholangiocarcinoma

MedlinePlus Genetics : 43 Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. They carry bile, which is a fluid that helps the body digest fats that are in food. Bile is made in the liver and stored in the gallbladder before being released in the small intestine after a person eats.Cholangiocarcinoma is classified by its location in relation to the liver. Intrahepatic cholangiocarcinoma begins in the small bile ducts within the liver. This is the least common form of the disease, accounting for less than 10 percent of all cases. Perihilar cholangiocarcinoma (also known as a Klatskin tumor) begins in an area called the hilum, where the right and left major bile ducts join and leave the liver. It is the most common form of the disease, accounting for more than half of all cases. The remaining cases are classified as distal cholangiocarcinomas, which begin in bile ducts outside the liver. The perihilar and distal forms of the disease, which both occur outside the liver, are sometimes grouped together and called extrahepatic cholangiocarcinoma.The three types of cholangiocarcinoma do not usually cause any symptoms in their early stages, and this cancer is usually not diagnosed until it has already spread beyond the bile ducts to other tissues. Symptoms often result when bile ducts become blocked by the tumor. The most common symptom is jaundice, in which the skin and whites of the eyes turn yellow. Other symptoms can include extreme tiredness (fatigue), itching, dark-colored urine, loss of appetite, unintentional weight loss, abdominal pain, and light-colored and greasy stools. These symptoms are described as "nonspecific" because they can be features of many different diseases.Most people who develop cholangiocarcinoma are older than 65. Because this cancer is often not discovered until it has already spread, it can be challenging to treat effectively. Affected individuals can survive for several months to several years after diagnosis, depending on the location of the cancer and how advanced it is.

MalaCards based summary : Cholangiocarcinoma, also known as cholangiocarcinoma, susceptibility to, is related to klatskin's tumor and gallbladder cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Cholangiocarcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Desflurane and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and small intestine, and related phenotypes are jaundice and biliary tract neoplasm

OMIM® : 57 Carcinomas of the biliary tract are aggressive malignancies, with 5-year survival of less than 10%. These carcinomas arise throughout the biliary tree and are anatomically classified as either intrahepatic or extrahepatic cholangiocarcinomas. Gallbladder carcinomas also arise from the biliary tree but have distinct natural histories compared to cholangiocarcinomas, suggesting different underlying tumor biology. Cholangiocarcinoma incidence varies widely between geographic regions, reflecting the impact of different underlying etiologies. In endemic areas, liver fluke infections by O. viverrini and Clonorchis sinensis, both group I carcinogens, represent the major risk factor for cholangiocarcinomas. In nonendemic regions, other risk factors, including choledochal cysts (603003), hepatolithiasis, and primary sclerosing cholangitis (613806), are likely contributors (summary by Chan-on et al., 2013). Overall, the majority of patients lack such identifiable risk factors (summary by Jiao et al., 2013). (615619) (Updated 05-Apr-2021)

KEGG : 36 Cholangiocarcinoma is a highly malignant neoplasm that carries a poor prognosis and lacks effective therapy. It is the second most common primary hepatic tumor, and it is increasing in incidence and carries a high mortality. The tumor arises from the ductular epithelium of the biliary tree, either within the liver (intrahepatic cholangiocarcinoma: ICC) or more commonly from the extrahepatic bile ducts (extrahepatic cholangiocarcinoma). Several studies have demonstrated mutations resulting in overexpression of K-ras and p53 genes. These genetic alterations are associated with a more aggressive phenotype in this cancer. Many reports have implicated overexpression of the tyrosine kinase proto-oncogenes c-erbB-2 (HER-2/neu) and c-Met, as well as cyclo-oxygenase-2 (COX-2) activity in intrahepatic cholangiocarcinoma.

Wikipedia : 73 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Related Diseases for Cholangiocarcinoma

Diseases related to Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 709)
# Related Disease Score Top Affiliating Genes
1 klatskin's tumor 33.1 MIR373 MALAT1
2 gallbladder cancer 31.3 MALAT1 H19 AFAP1-AS1
3 thyroid carcinoma 30.6 PANDAR NEAT1 MALAT1 H19 AFAP1-AS1
4 pancreatic ductal adenocarcinoma 30.5 MIR21 MIR148A MIR141 MALAT1 H19 AFAP1-AS1
5 renal cell carcinoma, nonpapillary 30.3 SPRY4-IT1 PANDAR MIR21 MIR204 MIR141 MALAT1
6 lung cancer susceptibility 3 30.2 MIR21 MIR200B MALAT1 H19 AFAP1-AS1
7 nasopharyngeal carcinoma 30.2 NEAT1 MIR21 MIR141 MALAT1 HULC H19
8 squamous cell carcinoma 30.2 SPRY4-IT1 SOX2-OT PCAT1 NEAT1 MALAT1 H19
9 kidney cancer 30.2 MIR21 MIR200B MIR141 MALAT1 H19
10 pancreatic cancer 30.1 SPRY4-IT1 NEAT1 MIR373 MIR21 MIR148A MIR141
11 small cell cancer of the lung 30.1 MIR21 MALAT1 CCAT2
12 hepatocellular carcinoma 30.1 SPRY4-IT1 SOX2-OT PCAT1 PANDAR NEAT1 MIR21
13 osteogenic sarcoma 30.1 SOX2-OT PCAT1 PANDAR NEAT1 MALAT1 HULC
14 melanoma 30.0 SPRY4-IT1 SOX2-OT MIR204 MIR200B MIR141 MALAT1
15 thyroid cancer, nonmedullary, 1 30.0 NEAT1 MALAT1 HULC H19
16 diffuse large b-cell lymphoma 30.0 PANDAR MIR320A MIR21 MIR200B HULC
17 myeloma, multiple 29.9 PCAT1 MIR21 MALAT1 H19
18 bladder cancer 29.9 SPRY4-IT1 PCAT1 PANDAR MIR21 MIR141 MALAT1
19 clear cell renal cell carcinoma 29.6 SPRY4-IT1 PANDAR MIR320A MIR21 MIR204 MALAT1
20 pancreas disease 29.6 MIR373 MIR21 MIR148A MIR141
21 laryngeal squamous cell carcinoma 29.6 NEAT1 MIR21 MIR148A MALAT1 H19
22 bladder disease 29.6 MIR21 MIR204 MIR148A MIR141
23 gastrointestinal system disease 29.5 MIR373 MIR21 MIR204 MIR200B MIR148A MIR141
24 gastrointestinal system cancer 29.4 MIR373 MIR21 MIR204 MIR200B MIR148A MIR141
25 gastric cancer 29.4 SPRY4-IT1 SOX2-OT PCAT1 PANDAR NEAT1 MIR21
26 esophageal cancer 29.3 PCAT1 MIR373 MIR21 MIR148A MIR141 MALAT1
27 oral squamous cell carcinoma 29.1 NEAT1 MIR373 MIR370 MIR21 MIR204 MIR200B
28 colorectal cancer 29.0 SPRY4-IT1 SOX2-OT PCAT1 PANDAR NEAT1 MIR320A
29 lung cancer 28.9 SPRY4-IT1 SOX2-OT PCAT1 PANDAR NEAT1 MIR373
30 breast cancer 28.5 SPRY4-IT1 SOX2-OT PTPN3 PANDAR NEAT1 MIR373
31 intrahepatic cholangiocarcinoma 11.9
32 contractural arachnodactyly, congenital 11.7
33 bile duct cancer 11.3
34 cholangitis, primary sclerosing 11.3
35 mucinous intrahepatic cholangiocarcinoma 11.2
36 sarcomatous intrahepatic cholangiocarcinoma 11.2
37 combined hepatocellular carcinoma and cholangiocarcinoma 11.2
38 biliary tract cancer 11.2
39 clonorchiasis 11.1
40 signet ring cell intrahepatic cholangiocarcinoma 11.1
41 opisthorchiasis 11.0
42 cholangitis 11.0
43 sclerosing cholangitis 10.9
44 convulsions, familial infantile, with paroxysmal choreoathetosis 10.8
45 obstructive jaundice 10.7
46 liver cirrhosis 10.7
47 liver disease 10.7
48 adenocarcinoma 10.6
49 cholestasis 10.5
50 hepatitis b 10.5

Graphical network of the top 20 diseases related to Cholangiocarcinoma:



Diseases related to Cholangiocarcinoma

Symptoms & Phenotypes for Cholangiocarcinoma

Human phenotypes related to Cholangiocarcinoma:

58 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 jaundice 58 31 hallmark (90%) Very frequent (99-80%) HP:0000952
2 biliary tract neoplasm 58 31 hallmark (90%) Very frequent (99-80%) HP:0100574
3 acholic stools 58 31 hallmark (90%) Very frequent (99-80%) HP:0011985
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
6 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
7 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
8 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
9 cholangiocarcinoma 31 HP:0030153

Clinical features from OMIM®:

615619 (Updated 05-Apr-2021)

UMLS symptoms related to Cholangiocarcinoma:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas; malaise

Drugs & Therapeutics for Cholangiocarcinoma

Drugs for Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desflurane Approved Phase 4 57041-67-5 42113
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Etomidate Approved Phase 4 33125-97-2 36339 667484
5
Meperidine Approved Phase 4 57-42-1 4058
6 Cyclooxygenase Inhibitors Phase 4
7 Cyclooxygenase 2 Inhibitors Phase 4
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4
9 Anesthetics, Inhalation Phase 4
10
Bilirubin Phase 4 635-65-4 5280352
11 Platelet Aggregation Inhibitors Phase 4
12 Anesthetics Phase 4
13
Bismuth Phase 4 7440-69-9 16682734 105143
14 Omega 3 Fatty Acid Phase 4
15 Analgesics Phase 4
16 Hypnotics and Sedatives Phase 4
17 Narcotics Phase 4
18 Anesthetics, General Phase 4
19 Analgesics, Opioid Phase 4
20 Anesthetics, Intravenous Phase 4
21 Ulipristal acetate Phase 4 126784-99-4
22 GABA Modulators Phase 4
23 Psychotropic Drugs Phase 4
24 Anti-Anxiety Agents Phase 4
25
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
26
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
27
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
28
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 3 14769-73-4 26879
29
nivolumab Approved Phase 3 946414-94-4
30
Ipilimumab Approved Phase 3 477202-00-9
31
Ivosidenib Approved, Investigational Phase 3 1448347-49-6 71657455
32
Citalopram Approved Phase 3 59729-33-8 2771
33
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
34
Dexetimide Withdrawn Phase 3 21888-98-2
35 Antibiotics, Antitubercular Phase 3
36 Anti-Bacterial Agents Phase 3
37 Hematinics Phase 3
38 Emetics Phase 3
39 Mitogens Phase 2, Phase 3
40 Pharmaceutical Solutions Phase 3
41 Antiparasitic Agents Phase 3
42 Tin Fluorides Phase 2, Phase 3
43 Anthelmintics Phase 3
44 Hematoporphyrin Derivative Phase 3
45 Cola Phase 3
46 Hematoporphyrins Phase 3
47 Antidepressive Agents Phase 3
48 Parasympatholytics Phase 3
49 Serotonin Uptake Inhibitors Phase 3
50 Cholinergic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 541)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
2 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
3 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
4 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
5 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
6 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
7 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
8 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
9 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
10 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
11 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study. Recruiting NCT04378023 Phase 4 Neoadjuvant Chemo-radiotherapy
13 Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
14 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial Unknown status NCT00653978 Phase 3
15 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
16 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
17 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
18 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
19 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
20 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
21 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
22 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
23 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
24 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Completed NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
25 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
26 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
27 Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT03771846 Phase 3 irinotecan, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
28 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
29 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
30 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Recruiting NCT02108145 Phase 2, Phase 3
31 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
32 Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency Recruiting NCT03345303 Phase 3 Bortezomib
33 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
34 A Randomized Controlled, Multicenter, Open, Seamless Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors Recruiting NCT04669496 Phase 2, Phase 3 Neoadjuvant treatment
35 The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
36 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
37 Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
38 A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3 Recruiting NCT04093362 Phase 3 TAS-120;Cisplatin/Gemcitabine
39 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
40 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Recruiting NCT04066491 Phase 2, Phase 3 Bintrafusp alfa;Placebo;Gemcitabine;Cisplatin
41 A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
42 Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
43 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Active, not recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
44 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Active, not recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
45 Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Active, not recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
46 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Active, not recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
47 Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
48 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
49 Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma Terminated NCT02200042 Phase 3
50 Photodynamic Therapy for Palliation of Unresectable Cholangiocarcinoma A Multicenter, Open Label, Randomized, Controlled Phase III Trial Terminated NCT00907413 Phase 3

Search NIH Clinical Center for Cholangiocarcinoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cholangiocarcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cholangiocarcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Cholangiocarcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Genetic Tests for Cholangiocarcinoma

Genetic tests related to Cholangiocarcinoma:

# Genetic test Affiliating Genes
1 Cholangiocarcinoma, Susceptibility to 29
2 Cholangiocarcinoma 29

Anatomical Context for Cholangiocarcinoma

MalaCards organs/tissues related to Cholangiocarcinoma:

40
Liver, Lymph Node, Small Intestine, Pancreas, Colon, Endothelial, Neutrophil

Publications for Cholangiocarcinoma

Articles related to Cholangiocarcinoma:

(show top 50) (show all 13317)
# Title Authors PMID Year
1
Necroptosis microenvironment directs lineage commitment in liver cancer. 57 61
30209397 2018
2
The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. 47 54 61
19070389 2009
3
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. 57
24185509 2013
4
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. 57
24185513 2013
5
miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. 61 47
21086164 2011
6
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. 47 61
20146264 2010
7
Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. 47 61
17621267 2008
8
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. 47 61
16762633 2006
9
Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma. 54 61
20149523 2010
10
Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor. 61 54
19904746 2010
11
Nerve growth factor-beta expression is associated with lymph node metastasis and nerve infiltration in human hilar cholangiocarcinoma. 61 54
20119692 2010
12
The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis. 61 54
20524437 2010
13
Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. 61 54
20040392 2010
14
Significance of mucin expression in pancreatobiliary neoplasms. 61 54
19787286 2010
15
[Detection of lymph node micrometastasis for patients with extrahepatic cholangiocarcinoma and its prognostic significance]. 61 54
20450726 2010
16
Current research in perineural invasion of cholangiocarcinoma. 61 54
20219134 2010
17
Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. 61 54
20135719 2010
18
The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. 54 61
19956064 2010
19
Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma. 54 61
19723119 2009
20
Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. 54 61
19639217 2009
21
Monoclonal antibodies against human aspartyl (asparaginyl) beta-hydroxylase developed by DNA immunization. 61 54
19663697 2009
22
Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion. 61 54
19631667 2009
23
Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. 61 54
19291182 2009
24
Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. 61 54
18948067 2009
25
Overexpression of adenovirus-mediated p27kip1 lacking the Jab1-binding region enhances cytotoxicity and inhibits xenografted human cholangiocarcinoma growth. 61 54
19528460 2009
26
Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma. 61 54
19621664 2009
27
ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines. 54 61
19414361 2009
28
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. 61 54
19319137 2009
29
Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. 54 61
19405942 2009
30
Resistance of cholangiocarcinoma cells to parthenolide-induced apoptosis by the excretory-secretory products of Clonorchis sinensis. 54 61
19066964 2009
31
Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. 54 61
19212669 2009
32
Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. 54 61
19218340 2009
33
Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. 61 54
18395502 2009
34
Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. 61 54
19055478 2009
35
Inflammation and tumor progression: a lesson from TNF-alpha-dependent FAK signaling in cholangiocarcinoma. 54 61
19347283 2009
36
A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. 54 61
19262069 2009
37
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. 54 61
19084911 2008
38
Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. 54 61
18854271 2008
39
[Expression of mucin glycoproteins and cytokeratins in intrahepatic cholangiocarcinoma]. 61 54
19094709 2008
40
Regulation of Wnt/beta-catenin pathway by cPLA2alpha and PPARdelta. 54 61
18636547 2008
41
[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma]. 61 54
19173916 2008
42
Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges? 61 54
18329969 2008
43
Bile acids repress E-cadherin through the induction of Snail and increase cancer invasiveness in human hepatobiliary carcinoma. 61 54
18691339 2008
44
BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. 61 54
18723481 2008
45
Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. 61 54
18495210 2008
46
c-Met targeted therapy of cholangiocarcinoma. 54 61
18494048 2008
47
Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. 61 54
18329694 2008
48
Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein. 54 61
18407604 2008
49
Aberrant expression of alpha-fetoprotein in intrahepatic cholangiocarcinoma: an exceptional occurrence. 54 61
18417680 2008
50
A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. 54 61
18081149 2008

Variations for Cholangiocarcinoma

Copy number variations for Cholangiocarcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 111150 17 35097918 35138441 Copy number ERBB2 Cholangiocarcinoma
2 118016 17 7512444 7519279 Copy number TP53 Cholangiocarcinoma
3 159441 21 42600000 48129895 Amplification TFF1 Cholangiocarcinoma
4 159442 21 42600000 48129895 Amplification TFF2 Cholangiocarcinoma
5 159443 21 42600000 48129895 Amplification TFF3 Cholangiocarcinoma

Expression for Cholangiocarcinoma

Search GEO for disease gene expression data for Cholangiocarcinoma.

Pathways for Cholangiocarcinoma

Pathways related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.51 MIR373 MIR21 MIR200B MIR152 MIR141

GO Terms for Cholangiocarcinoma

Cellular components related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 8.8 MIR21 MIR152 MIR148A

Biological processes related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.67 MIR21 MIR204 MIR200B MIR152
2 negative regulation of cell migration GO:0030336 9.58 MIR320A MIR21 MIR204
3 positive regulation of cell cycle arrest GO:0071158 9.43 MIR200B MIR152
4 negative regulation of blood vessel endothelial cell migration GO:0043537 9.43 MIR204 MIR200B MIR152
5 gene silencing by miRNA GO:0035195 9.36 NEAT1 MIR373 MIR370 MIR320A MIR21 MIR204
6 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.32 MIR21 H19
7 miRNA mediated inhibition of translation GO:0035278 9.26 MIR21 MIR204 MIR200B MIR148A
8 negative regulation of superoxide dismutase activity GO:1901670 9.16 MIR21 H19

Molecular functions related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.26 MIR21 MIR200B MIR152 MIR141
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR373 MIR320A MIR21 MIR204 MIR200B MIR152

Sources for Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....